Shwachman-Diamond syndrome (SDS) is an autosomal recessive disease characterized by exocrine pancreatic insufficiency, bone marrow failure, increased risk of acute myeloid leukemia, and other variable developmental abnormalities. The molecular mechanisms underlying the pathogenesis of SDS are currently unknown. The SDS gene (named SBDS) is predicted to encode a highly conserved, novel protein of unknown function that is ubiquitously expressed throughout human tissues. SBDS has been postulated to function in RNA processing based on indirect evidence in orthologues. We have established and characterized cell lines from a series of SDS patients followed at Children's Hospital and have generated an antibody against the SBDS protein. In project 1, we will investigate SBDS protein function using three experimental approaches: A. Immunoprecipitation of the SBDS protein complex to identify associated protein binding partners; B. Identification of the regulatory factors controlling the intracellular localization of SBDS; and C. Investigation of the postulated role of SBDS in RNA processing by assessing SBDS RNA binding, association with ribonucleoprotein complexes, and ribosomal RNA maturation. Project 2 involves the characterization of the cellular phenotype of SBDS-/- cells. Biochemical processes regulating cell cycle progression, apoptosis, and response to genotoxic and cellular stressors will be interrogated. All cellular SDS phenotypes will be validated by assaying for genetic rescue following the introduction of the wild-type SBDS cDNA. The identification of a cellular SDS phenotype will provide a functional assay with which to assess any SBDS-interacting proteins identified in Project 1. In Project 3, SBDS function in development and disease will be studied by generating an SBDS-/- mouse. SDS thus provides a disease model to study fundamental molecular processes contributing to marrow failure and leukemogenesis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL079582-06
Application #
7534622
Study Section
Special Emphasis Panel (ZHL1-CSR-D (S1))
Program Officer
Qasba, Pankaj
Project Start
2004-09-30
Project End
2009-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
6
Fiscal Year
2008
Total Cost
$333,759
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Burwick, Nicholas; Zhang, Michael Y; de la Puente, Pilar et al. (2017) The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res 55:23-32
Myers, Kasiani C; Bolyard, Audrey Anna; Otto, Barbara et al. (2014) Variable clinical presentation of Shwachman-Diamond syndrome: update from the North American Shwachman-Diamond Syndrome Registry. J Pediatr 164:866-70
Stumpff, Jason; Ghule, Prachi N; Shimamura, Akiko et al. (2014) Spindle microtubule dysfunction and cancer predisposition. J Cell Physiol 229:1881-3
Ruggero, Davide; Shimamura, Akiko (2014) Marrow failure: a window into ribosome biology. Blood 124:2784-92
Tulpule, Asmin; Kelley, James M; Lensch, M William et al. (2013) Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell 12:727-36
Burwick, Nicholas; Shimamura, Akiko; Liu, Johnson M (2011) Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome. Semin Hematol 48:136-43
Huang, James N; Shimamura, Akiko (2011) Clinical spectrum and molecular pathophysiology of Shwachman-Diamond syndrome. Curr Opin Hematol 18:30-5
Sakamoto, Kathleen M; Shimamura, Akiko; Davies, Stella M (2010) Congenital disorders of ribosome biogenesis and bone marrow failure. Biol Blood Marrow Transplant 16:S12-7
Parmar, Kalindi; Kim, Jungmin; Sykes, Stephen M et al. (2010) Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 28:1186-95
Rosenberg, Philip S; Zeidler, Cornelia; Bolyard, Audrey A et al. (2010) Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 150:196-9

Showing the most recent 10 out of 18 publications